LYZL2

Across TCGA pan-cancer cohorts, LYZL2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LYZL2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYZL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYZL2 expression acts as an unfavorable survival marker.

HNSC and PRAD are the cancer types where LYZL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.212	0.666	.007	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LYZL2–HNSC (DFS)

Open the HNSC breakdown →